Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.50 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25810523 | 0.83 | SLC7A5 (0.55) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL11818 | 0.82 | PLK1 (0.61) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL1569614 | 0.82 | SLC7A5 (0.60) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL1569612 | 0.82 | SLC7A5 (0.60) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL31310149 | 0.81 | MRGPRX4 (0.49) | HDAC8HDAC6MRGPRX4MEN1KMT2A | |
| SCHEMBL246858 | 0.81 | SLC7A5 (0.59) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL2536532 | 0.81 | SLC7A5 (0.59) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL6388386 | 0.81 | LOXL2 (0.65) | SLC7A5HDAC8HDAC6MRGPRX4ALDH1A1 | |
| SCHEMBL16103849 | 0.81 | SLC7A5 (0.59) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 | |
| SCHEMBL14541727 | 0.81 | SLC7A5 (0.59) | SLC7A5HDAC8HDAC6MRGPRX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-113173924-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-29 | — | — | US | disclosed |
| EP-3307715-A1 | AROMATIC SULFONAMIDE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| CN-107848974-A | Aromatic sulfonamide derivatives | 拜耳制药股份公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2016198374-A1 | AROMATIC SULFONAMIDE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | SLC7A5 4282/4885HDAC8 58/4885HDAC6 884/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | SLC7A5 4201/4885HDAC8 1543/4885HDAC6 543/4885 |
| US-20180338980-A1 | AROMATIC SULFONAMIDE DERIVATIVES | ARSA, SULT2A1, TPST2 | SLC7A5 1140/4885HDAC8 1244/4885HDAC6 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.